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doi:10.1Objective: Endovascular stent grafting represents a novel concept for type B aortic dissection both in the acute
and subacute/chronic setting, with an unknown effect on outcomes.
Methods: In a prospective trial 140 patients with stable type B dissection were randomly subjected to elective
stent-graft placement in addition to optimal medical therapy (n ¼ 72) or to optimal medical therapy (n ¼ 68)
with surveillance (arterial pressure according to World Health Organization guidelines120/80 mm Hg). The pri-
mary end point was 1-year all-cause mortality, whereas aorta-related mortality, progression (with need for conver-
sion or additional endovascular or open surgical intervention), and aortic remodeling were secondary end points.
Results: There was no difference in all-cause mortality: cumulative survival was 97.0%  3.4% with optimal
medical therapy versus 91.3%  2.1% with thoracic endovascular aortic repair (P ¼ .16). Moreover, aorta-
related mortality was not different (P ¼ .42), and the risk for the combined end point of aorta-related death (rup-
ture) and progression (including conversion or additional endovascular or open surgical intervention) was similar
(P¼ .86). Three neurologic adverse events occurred in the thoracic endovascular aortic repair group (1 paraplegia,
1 stroke, and 1 transient paraparesis) versus 1 episode of paraparesis with medical treatment. Finally, aortic remod-
eling (with true-lumen recovery and thoracic false-lumen thrombosis) occurred in 91.3% with thoracic endovas-
cular aortic repair versus 19.4%with medical treatment (P<.001), which is suggestive of continued remodeling.
Conclusions: In survivors of uncomplicated type B aortic dissection, elective stent-graft placement does not improve
1-year survival and adverse events, despite favorable aortic remodeling. (J Thorac Cardiovasc Surg 2010;140:S101-8)Endovascular stent-graft repair is considered life-saving in
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The Journal of Thoracic and Cardpatients are traditionally managed conservatively (annual
survival 80%). However, long-term outcomes remain
sobering because of potential false-lumen expansion.4-6
The idea that membrane-coated stents might improve the
prognosis in patients with subacute/chronic type B dissec-
tion has been proposed.6
Although traditional management has focused on open sur-
gical intervention or medical management, endovascular re-
pair of aortic dissection is possible.1,2,7-10 However, there is
ongoing debate regarding clinically stable type B aortic
dissection, with current consensus in support of surveillance
and tight control of hypertension.7,11,12 Reports showing
both 30% mortality at 2 years6 and less than 50% long-term
survival12 have made thoracic endovascular aortic repair
(TEVAR) seem attractive as a possible alternative.MATERIALS AND METHODS
Study Design
Methodological aspects of the comparative trial have been described pre-
viously.6 The rationale was to compare conservative with endovascular
interventional treatment prospectively with regard to their effect on im-
proved outcomes.4,13-15
The study protocol was approved by the human rights and ethics com-
mittee at the coordinating center and by the local institutional review board
at each participating center. An independent data and safety monitoringiovascular Surgery c Volume 140, Number 6S S101
TABLE 1. Baseline characteristics of the patients
Characteristics Medical therapy (n ¼ 66) Medical therapy plus stent graft (n ¼ 70) P value
Age, y 59.9  11.6 60.3  10.6 .84*
Male sex, no. (%) 54 (81.8) 60 (85.7) .64y
Atherosclerosis/hypertension, no. (%) 54 (81.8) 59 (84.3) .82y
Marfan syndrome, no. (%) 0 (0) 2 (2.9) .50y
Hypertension only, no. (%) 10 (15.2) 7 (10.0) .44y
Unknown, no. (%) 2 (3.0) 2 (2.9) 1.00y
Diabetes mellitus, no. (%) 5 (7.6) 5 (7.1) 1.00y
Active smoking, no. (%) 17 (25.8) 14 (20.0) .54y
Pulmonary disease, no. (%) 9 (13.6) 7 (10.0) 0.60y
Body mass index 27.7  5.5 26.7  4.4 0.21*
NYHA classification, no. (%) .33z
I 51 (77.3) 55 (78.6)
II 11 (16.7) 14 (20.0)
III 4 (6.1) 1 (1.4)
ASA class, no. (%) .16z
I (healthy status) 20 (30.3) 23 (32.9)
II (mild systemic disease) 39 (59.1) 32 (45.7)
III (severe systemic disease) 7 (10.6) 15 (21.4)
Maximal diameter of dissected aorta, mm 43.5  9.2 44.2  9.5 .59x
Dissection morphology, no. (%) .56y
Confined to descending thoracic aorta 5 (7.6) 8 (11.4)
Thoracoabdominal extension 61 (92.4) 62 (88.6)
Re-entry, no. (%) .23z
No 23 (34.8) 20 (28.6)
Thoracic 14 (21.2) 8 (11.4)
Abdominal 24 (36.4) 33 (47.1)
Thoracoabdominal 5 (7.6) 9 (12.9)
False lumen, no. (%) .86y
Perfused 43 (65.2) 44 (62.9)
Perfused with partial thrombosis 23 (34.8) 26 (37.1)
Values are presented as means standard deviations where shown. NYHA, New York Heart Association; ASA, American Society of Anesthesiologists. *The P value was calculated
by using the 2-sample t test. yThe P value was calculated by using the Fisher’s exact test. zThe P value was calculated by using the c2 test. xThe P value was calculated by using the
Mann–Whitney U test.
Aortic Symposium 2010 Nienaber et alboard oversaw the conduct, safety, and efficacy of the trial in scheduled
adjudication meetings and decided to continue the trial on the basis of an
interim analysis after enrolling half the required number of patients. Data
management and statistical analyses were performed by the coordinating
center at the University of Rostock.
Study Population
Consecutive patients with type B aortic dissection in the subacute/
chronic phase were included at 7 centers in Germany, Italy, and France. Pa-
tients were considered unsuitable for randomization in the presence of tra-
ditional indications for endovascular or open surgical intervention
(diameter6 cm) or in the presence of acute complications. After an interim
of at least 14 days to identify early complications and exclude spontaneous
false-lumen thrombosis, all patients were considered subacute or chronic
cases. Randomization was carried out at a 1:1 ratio centrally by means of
a computer-generated permuted-block sequence. Written informed consent
was obtained.
Interventional Procedures
Individually selected stent grafts (TALENT; Medtronic, Inc, Santa Rosa,
Calif) were used to scaffold up to 20 cm of dissected thoracic aorta. The pro-
cedure was performed with digital angiography and transesophageal ultra-
sonography. The femoral artery could usually accommodate the 24F
stent-graft system, which was advanced over a 260-cm stiff wire navigatedS102 The Journal of Thoracic and Cardiovascular Surin the true lumen and deployed under rapid pacing.16,17 Intentional coverage
of the left subclavian artery (LSA) was accepted to avoid endoleak; surgical
revascularization of the LSA was performed at the discretion of the operator.
In the presence of a lusorian artery, incomplete circle of Willis, or dominant
left vertebral artery, an LSA bypass was placed before stenting.15,18,19
Clinical Outcome and End Points
Clinical outcome and events were classified in accord with reporting
standards of the Ad Hoc Committee for Standardized Reporting Practices
in Vascular Surgery/International Society for Cardiovascular Surgery.15,20
An outcomes adjudication committee consisting of a cardiac surgeon, 2
vascular surgeons, and 2 cardiac interventionalists assessed each
complication independently in blinded fashion; potential disagreements
were planned to be resolved by consensus. With serial tomographic
imaging at 3 and 12 months, all patients underwent evaluation for false-
lumen thrombosis and true-lumen dimensions at the level of the nondis-
sected and dissected aorta.
Statistical Analysis
Based on previous observational evidence with an expected reduction of
the primary end point from 20% to 3% to 5% in the stent-graft group, a sam-
ple size of 140 patients was required for 80% power to detect a difference,
with a 2-sided a error of .05. Sample size was determined by using the study
planning software nQuery Advisor 7.0 (Statcon, Witzenhausen, Germany).gery c December 2010
FIGURE 1. Graphic display of individual time intervals between onset of type B dissection and randomization in both groups. A, Medical treatment group;
B, stent graft group.
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yses. Data were processed with the SPSS/PC Software package version 15.0
(SPSS, Inc, Chicago, Ill). For continuous variables, differences were evalu-
ated by use of the 2-sample t test or nonparametric Mann–Whitney U test.
Categorical variables were compared by using the Fisher’s exact test or c2
test. Time-to-event curves were calculated by using the Kaplan–Meier
method and compared by using the log-rank test on an intent-to-treat basis.
All tests were 2-tailed.RESULTS
Patients’ Characteristics and Treatment Assignment
Over a sample period of 2 years, 140 patients met the in-
clusion criteria and were randomly assigned to elective TE-
VAR with optimal medical therapy or optimal medical
treatment alone. Two patients did not undergo stent-graft
placement after randomization because of declined consent
in one and sudden death in another; 2 patients eventually de-
clined medical treatment and opted for early stent-graft
placement, although they were randomized differently.TABLE 2. Procedural characteristics (medical therapy and TEVAR)
Time from dissection to stent graft, d, median (range) 82 (14–360)
General anesthesia, no. (%) 68 (97.1)
Duration of procedure, min, median (range) 108 (20–200)
Intraprocedural death, no. (%) 0 ()
Procedural success, no. (%) 67 (95.7)
No. of stent grafts per patient, no., median (range) 1.34 (1–3)
Femoral access, no. (%) 66 (94.3)
Occlusion of LSA, no. (%) 17 (24.3)
Carotid–subclavian bypass, no. (%) 2 (2.9)
Access vessel patch repair, no. (%) 1 (1.4)
Hospital stay, d, median (range) 8 (5–29)
ICU stay, h, median (range) 23 (12–128)
LSA, Left subclavian artery; ICU, intensive care unit.
The Journal of Thoracic and CardOverall, 140 patients were followed in both groups, with
72 patients in the endovascular arm and 68 in the medical
treatment arm on an intent-to-treat basis; all patients had
protocol-guided follow-up.
Baseline and demographic characteristics, comorbidity
profiles and risk factors, distribution of the American Soci-
ety of Anesthesiologists classification, and dissection mor-
phology were evenly distributed. Moreover, the time
interval between onset of dissection and randomization
was identical between the groups, with a median of 45 and
39 days, respectively, reflecting the early phase of chronic
disease (Table 1). The median interval between randomiza-
tion and stent-graft placement was 12 days (range, 4–29
days; Figure 1). Procedural details and hospital stay are
shown in Table 2.
TEVAR was successfully completed in 70 patients, with
no intraprocedural conversion to open surgical interven-
tion; there were no complications related to generalTABLE 3. Periprocedural outcomes (30 days)
Mortality, no. (%) 2 (2.8)
Periprocedural events
Retrograde type A dissection, no. (%) 1 (1.5)
Rupture of iliac access vessel, no. (%) 1 (1.5)
Conversion to open surgical intervention, no. (%) 0 ()
Ancillary procedures, no. (%) 3 (4.5)
Stenting of iliac artery 1 (1.5)
Aortic stent-graft extension 1 (1.5)
Aortic bare stent extension 1 (1.5)
Periprocedural neurologic events, no. (%)
Paraplegia/paraparesis 2 (2.9)
Major stroke 1 (1.5)
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FIGURE 2. A, Kaplan–Meier estimates of 1-year overall cumulative survival in both groups (P ¼ .16. log-rank test). B, Kaplan–Meier estimates of 1-year
aorta-related survival in both groups (P ¼ .42, log-rank test). C, Kaplan–Meier estimates of 1-year cumulative freedom from the combined end point of
progression and adverse events; the combined end point consisted of related death, conversion, and ancillary interventions (including a second stent-graft
procedure, access revision, and peripheral interventions). Endovascular interventions (conversion to TEVAR in the control group or additional
TEVAR in the stent-graft group) are an integral part of the combined end point of progressive aortic pathology. There was no difference between groups
(P ¼ .53, log-rank test).
Aortic Symposium 2010 Nienaber et alanesthesia or ventilation. A single stent graft was inserted
in 58 (82.9%) patients, 2 grafts in 8 (11.4%) patients,
and 3 grafts in 4 (5.7%) patients. Intentional occlusion
of the LSA without prior revascularization was docu-
mented in 17 (24.3%) patients, with no neurologic
sequelae or need for revascularization. Periprocedural out-
comes (30 days) included 3 vascular injuries requiringS104 The Journal of Thoracic and Cardiovascular Surancillary procedures and 3 cases of neurologic complica-
tions with 1 paraplegia, 1 transient paraparesis in the pres-
ence of extensive coverage (3 stent grafts) with LSA
occlusion (without prior revascularization), and 1 stroke.
Normalized arterial pressure (120/80 mm Hg) was docu-
mented in all patients 1 month after randomization and at
follow-up visits in both groups (Table 3).gery c December 2010
TABLE 4. Events within 1 year of randomization
Medical Stent graft P value
Overall mortality, no. (%) 2 (3.0) 6 (8.6) .28
Aorta-related mortality, no. (%) 2 (3.0) 4 (5.7) .68
Secondary interventions, no. (%) 9 (13.6) 10 (14.3) 1.00
Crossover 7 (10.6) 0 () .005
Conversion to surgical intervention 1 (1.5) 1 (1.4) 1.00
Stent-graft extension 0 () 5 (7.1) .058
Aortic bare stent extension 0 (-) 1 (1.4) 1.00
PTA/access vessel repair 1 (1.5) 3 (4.2) .62
Adverse events, no. (%)
Persistent paraplegia/paraparesis 1 (1.5) 2 (2.9) 1.00
Nienaber et al Aortic Symposium 2010Primary Outcome
Figure 2, A, shows cumulative all-cause survival (esti-
mated with the use of Kaplan–Meier curves) in both groups.
Comparison between curves revealed no significant differ-
ences (P ¼ .16, log-rank test). Survival probability at 1
year was 91.3%  2.1%% with TEVAR and 97.0% 
3.4% with medical treatment. Unadjusted Cox regression
analysis for all-cause survival revealed a hazard ratio of
0.34 with a 95% confidence interval from 0.068 to 1.670
(P ¼ .183); with 9 fatalities, the death rate did not achieve
the assumption of 28 events to achieve statistical power.Major stroke 0 () 2 (2.9) .50
Myocardial infarction 0 () 0 () 
The P values were calculated by using the Fisher’s exact test. PTA, Percutaneous trans-
luminal angioplasty.Secondary End Points
Figure 2, B, depicts freedom from aorta-related death (P¼
.44, log-rank test), with a survival probability of 94.2% 
2.8% with TEVAR and 97.0%  2.1% with medical treat-
ment alone. Analysis of individual fatalities revealed that 4
patients had been included despite protocol violations (1
acute malperfusion case on dialysis, 2 cases of acute leg is-
chemia, and 1 patient with ongoing pain and extra-aortic
blood collection since onset of dissection).
Figure 2, C, illustrates the Kaplan–Meier analysis of
a combined end point of aorta-related death, crossover/con-
version for expansion, and ancillary procedures, revealing
no differences between groups (P ¼ .86, log-rank test).
Cumulative freedom from the combined end point was
82.5%  .4.7% with optimal medical treatment and
83.3%  4.6% with additional stent grafting.
Table 4 summarizes all events, including overall and
aorta-related mortality since randomization. Aortic expan-
sion of greater than 60 mm was more prevalent with medical
treatment and followed by crossover to TEVAR in 11.2%
of patients and conversion to open surgical intervention in
4.4% of patients; 1 patient crossed over for late malperfu-
sion syndrome. There were 2 cases of ischemic spinal
cord injury after stent grafting and 1 with medical therapy
(P ¼ .91); the latter patient had true-lumen collapse with
malperfusion to various pairs of intercostal arteries 11
months after dissection, followed by late conversion to
stent-graft placement. With TEVAR, all aorta-related deaths
had occurred within 2 months. An additional stent graft for
false-lumen expansion was required in 6 patients, whereas 3
patients converted to open surgical intervention for either
expansion, retrograde type A dissection, or malperfusion.
All crossover cases from medical treatment to TEVAR
had an uneventful outcome, no mortality, and documented
aortic remodeling.Clinical Follow-up and Aortic Remodeling
Table 5 summarizes morphologic evolution over time in
both groups and evidence of aortic remodeling. Although
baseline dimensional variables were similar, placement of
a stent graft was followed by expansion of the thoracicThe Journal of Thoracic and Cardtrue lumen from 17.4  10.7 to 25.7  6.7 mm at 3 months,
with further expansion to 27.1 7.0 mm at 1 year (P<.001)
at level D; similar changes were documented at level C. Si-
multaneously, maximal false-lumen diameter shrank from
26.9 10.9 to 17.2 13.7 mm at 3 months after stent graft-
ing (P< .001) and to 14.6  14.7 mm at 1 year at levels C
and D (P< .001). Moreover, the process of false-lumen
thrombosis in the thoracic aorta was enhanced after stent-
graft placement, with 92.6% complete false-lumen throm-
bosis and morphologic evidence of aortic remodeling (P<
.001), as exemplified in Figure 3. Conversely, medical treat-
ment alone failed to demonstrate true-lumen recovery or
false-lumen shrinkage from remodeling.DISCUSSION
The Investigation of Stent Grafts in Patients with Type B
Aortic Dissection (INSTEAD) trial showed, for the first
time, that medical management for uncomplicated type B
aortic dissection portends excellent survival as long as
tight blood pressure control and close surveillance are
ensured.11,21,22 However, for patients not responding to
medical management with progressive expansion or
malperfusion, deferred endovascular therapy is feasible and
safe.
Although the concept of endovascular stent grafting has
been embraced to replace open surgical intervention for
complicated type B dissection (even without any randomized
data),10,23,24 revelations of the INSTEAD trial do not
challenge the perception of an endovascular alternative to
open surgical intervention. Instead, the potential of
endografting to remodel the dissected aorta25 and address
late expansion or malperfusion has been confirmed.26 Yet
TEVAR in stable low-risk patients did not improve first-year
survival and was associated with spinal injury in 2.8%, as
expected from previous observations.23,24,27,28 Thus the
perception that prophylactic scaffolding is a better
alternative to tailored medical management has been blurred,iovascular Surgery c Volume 140, Number 6S S105
TABLE 5. Morphologic characteristics over time (remodeling)
Characteristics Medical therapy (n ¼ 66) Medical therapy plus stent graft (n ¼ 70) P value
Baseline type B dissection
Maximum aortic diameter 43.6  9.2* 44.1  9.6 .65z
True-lumen diameter at level C 20.3  9.3 19.4  8.0* .55y
False-lumen diameter at level C 27.7  11.6 29.3  12.4* .65z
True-lumen diameter at level D 17.3  8.7 17.4  10.7* .91y
False-lumen diameter at level D 24.0  10.4 26.9  10.9* .13y
3-mo CT follow-up
Maximum aortic diameter 46.2  11.1 44.7  8.3 .75z
True-lumen diameter at level C 21.9  8.8 30.6  6.0 <.001y
False-lumen diameter at level C 29.4  15.0 14.0  14.2 <.001y
True-lumen diameter at level D 17.1  8.8 25.7  6.7 <.001y
False-lumen diameter at level D 27.4  12.9 17.2  13.7{ <.001y
1-y CT follow-up
Maximum aortic diameter 45.5  7.9 44.7  11.9 .37z
True-lumen diameter at level C 23.9  9.9 31.8  5.9 <.001y
False-lumen diameter at level C 24.7  15.5 13.1  18.9 <.001z
True-lumen diameter at level D 19.3  9.0 27.1  7.0 <.001y
False-lumen diameter at level D 24.8  11.5 14.6  14.7 <.001y
False-lumen thrombosis
Complete, no. (%) 25 (37.9) 63 (92.6)k <.001x
Incomplete, no. (%) 6 (9.1) 5 (7.1) .76x
Values are presented as means  standard deviations where shown. CT, Computed tomographic. *P<.001 versus 3 months and 1 year. yThe P value was calculated by using the
2-sample t test. zThe P value was calculated by using the Mann-Whitney U test. xThe P value was calculated by using the Fisher’s exact test. kN ¼ 68. {P< .001 versus 1 year
(repeated-measures analysis).
FIGURE 3. Gadolinium-enhanced sagittal magnetic resonance images of type B dissection before and after endovascular repair: serial computed tomo-
graphic transverse images demonstrate thrombosis and remodeling after stent grafting within 1 year.
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Nienaber et al Aortic Symposium 2010given that there were some cases of expansion and late rupture
that occurred regardless of therapy. Considering the benefit of
carefully monitored pharmacotherapy, TEVAR appears
appropriate in cases of emerging complications: all patients
crossing over to TEVAR had an uneventful follow-up with re-
modeling despite rather late intervention.29,30
Thus the INSTEAD trial supports the notion of a com-
plication-specific approach instead of TEVAR for all
type B dissections. Survivors of type B dissection sub-
jected to best medical management have an excellent
outcome, but surveillance is needed to identify progres-
sion and to select patients for crossover to TEVAR or
ancillary procedures.
Although the concept of prophylactic scaffolding to ini-
tiate remodeling is intriguing and intuitively promising,
longer follow-up in larger cohorts is probably warranted
to reveal differences. Nevertheless, the mortality observed
in both the medical and endovascular groups was consid-
erably lower than expected, a frequent observation in con-
trolled randomized trials based on historic mortality data.
Thus the INSTEAD trial calls for reappraisal of standard-
ized care with blood pressure control and surveillance for
patients with distal dissection regardless of treatment. Tai-
lored medical management (in patients with uncompli-
cated type B dissection) avoids procedure-related adverse
events, but patients should be followed for late complica-
tions. Nevertheless, corroborating previous findings, the
INSTEAD trial confirmed that stent grafts enhance false-
lumen thrombosis and aortic remodeling in 92% of
cases.25,31
The INSTEAD trial focused on cases of uncomplicated
type B dissection that reached the subacute/chronic phase,
between 2 and 52 weeks of onset, with a largely heteroge-
neous risk profile. Improved selection algorithms might
help to identify those subsets of ‘‘stable’’ patients likely to
benefit from prophylactic scaffolding.32,33 Advancing
TEVAR technology and growing operator skills are likely
to avoid procedure-related adverse events, thus lowering
the threshold for use of TEVAR in asymptomatic patients
at risk despite best medical management.30 Our current pic-
ture of clinical care is transient, and our current views of best
management will soon be dated; both might be supplanted
by growing insight into disease progression in patients
with ‘‘asymptomatic’’ or ‘‘uncomplicated’’ dissection.
New interventional platforms and improved devices will
emerge and address current stent-graft inadequacies.34 Fu-
ture trials should focus on defined subgroups to test prophy-
lactic use of refined and dedicated endografts.
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